← Back

Wire · operational-macro

422: FDA's search for a new leader, and China's largest drugmakers

Published

21 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at finance.biggo.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Pfizer CEO Albert Bourla signals a strategic shift as Chinese drugmakers become primary competitors. The FDA faces setbacks with drug rejections and political challenges in leadership nomination, while new Treasury rules may restrict certain U.S.-China biotech equity deals but preserve licensing.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must rethink your US-China partnership plans as new Treasury rules threaten equity deals but spare licensing. If you target biopharma markets, the FDA's unsettled leadership and rising Chinese competitors will reshape your competitive and compliance priorities.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechchina-biotechfda-leadershipus-china-relationsdrug-approvaltreasury-rules